FDA clears Boston Scis Renegade HI-FLO for embolisms

TriMed Staff | | Health Imaging | Practice Management
The FDA has approved Boston Scientific’s Renegade HI-FLO Fathom system for selective access and delivery of diagnostic, embolic and therapeutic materials to the peripheral vasculature.

According to company, the Renegade HI-FLO is intended for use by interventional radiologists to treat uterine fibroids and liver cancer. Natick, Mass.-based Boston Scientific said that the system combines turn-for-turn torque response with the Fathom-16 and the Renegade HI-FLO Microcatheter pre-loaded as a single platform, which will be adaptable to a range of embolization procedures via eight configurations.

TriMed Staff

Related Content

Newly launched report feature provides patients with a visual aid to their imaging
Center for Devices and Radiological Health hit with federal job cuts
Overview of the regulatory landscape of AI in radiology
Concerns about private equity's growing influence in radiology
'Ad hoc' shifts and radiology 'maestros': How one department addressed its workflow hiccups
Not all lead glasses are created equal

Around the web

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care. 

Cardiovascular Business
Continuation of 99mTc-PYP shortage prompts need for alternative cardiac amyloidosis imaging

After three years of intermittent shortages of nuclear imaging tracer technetium-99m pyrophosphate, there are no signs of the shortage abating.